Novo-Backed Biotech Hemab Raises $301.5 Million in Upsized IPO
✨ AI Summary
🔊 جاري الاستماع
Hemab Therapeutics Holdings Inc., a clinical-stage biotechnology company that counts Novo Nordisk Foundation as one of its biggest investors, raised $301.5 million in an upsized US initial public offering that priced at the top of a marketed range.
